Hormonal contraceptives and systemic lupus erythematosus and rheumatoid arthritis
ESC Congress Library. Semedo Leite T. May 28, 2014; 50488; A-072
Dr. Tatiana Semedo Leite
Dr. Tatiana Semedo Leite
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)


Objective(s): Women with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and their clinicians may have unique concerns about hormonal methods of contraception, however pregnancy can be particularly risky in women with active disease or on teratogenic medications making contraception an important issue for women, particularly in the case of SLE. Furthermore, we believe that knowledge of disease flares and the influence of hormonal contraception could have implications for counselling patients on prevention to control their disease if they are able to predict a flare, and though have impact on quality of life.

The aim of our study is to evaluate the influence of hormonal contraception in systemic lupus erythematosus and rheumatoid arthritis disease course and study self-reported flares related to the use of hormonal contraceptives and when not under them.

Design & Methods: This study was performed by evaluating the women's files attending the Autoimmune Diseases' medical appointment at Faro's hospital between January 2013 and December 2013. Additionally, these patients underwent a questionnaire pre-coded with an ID number to allow review of the data and confirmation of information provided by the patient when needed. Functional ability was assessed using the Health Assessment Questionnaire (HAQ).

Before its beginning, this study got the Ethics' Commission approval. Statistical analysis was performed using SPSS 18.0.

Results: at the time of the call for abstracts, data is still being collected, so there is a lack of definitive results. These results are being collected into 2 groups: those with SLE and those with RA. Data collected, beyond women's demographic characteristics,is including information about the onset of disease and its relation with hormonal contraception, regularity and evolution of menstrual cycle and related flares with and without hormonal contraceptive methods. Signs of disease severity were taken in account.

Conclusions: Because results are still being collected and soon will be under statistical analysis, we do not have still definitive conclusions. However, we speculate from studying these patients in clinic that there were not more complains or adverse outcomes when using these contraceptive methods in selected cases. In what concerns specifically to RA, and in accordance to previous studies, hormonal contraception seems to have beneficial outcomes.

    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings